Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.40 |
| ▸ | DRD3 | P35462 | 8/20 | 0.40 |
| ▸ | BCHE | P06276 | 3/20 | 0.36 |
| ▸ | ACHE | P22303 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19886482 | 0.90 | DRD2 (0.39) | DRD2DRD3ACHEALDH1A1KMT2A | |
| SCHEMBL19874109 | 0.90 | DRD2 (0.40) | DRD2DRD3ALDH1A1GAAKMT2A | |
| SCHEMBL19874111 | 0.90 | DRD2 (0.40) | DRD2DRD3ALDH1A1GAAKMT2A | |
| SCHEMBL10285232 | 0.82 | ACHE (0.42) | DRD2DRD3ACHEKDM4EALDH1A1 | |
| SCHEMBL2794854 | 0.81 | CHRM2 (0.46) | ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL19874403 | 0.79 | DRD2 (0.33) | DRD2DRD3ALDH1A1 | |
| SCHEMBL19874400 | 0.79 | DRD2 (0.33) | DRD2DRD3ALDH1A1 | |
| SCHEMBL1105716 | 0.76 | ACHE (0.41) | DRD2DRD3ACHEALDH1A1KMT2A | |
| SCHEMBL19893177 | 0.76 | ADORA1 (0.41) | DRD2DRD3ACHEALDH1A1KMT2A | |
| SCHEMBL19874372 | 0.75 | NR1H2 (0.36) | DRD2DRD3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107531705-B | Bicyclic ketone sulfonamide compounds | 美国安进公司 | 2020-09-18 | — | — | CN | disclosed |
| US-10472356-B2 | Bicyclic ketone sulfonamide compounds | AMGEN INC. (US) | 2019-11-12 | — | — | US | disclosed |
| EP-3265465-B1 | BICYCLIC KETONE SULFONAMIDE COMPOUNDS | AMGEN INC (US) | 2019-04-24 | — | — | EP | disclosed |
| US-20180051021-A1 | BICYCLIC KETONE SULFONAMIDE COMPOUNDS | AMGEN INC. (US) | 2018-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10472356-B2 | Bicyclic ketone sulfonamide compounds | TRPV1, TRPA1, KCNJ11 | DRD2 3378/4885DRD3 3006/4885BCHE 2356/4885 |
| US-20180051021-A1 | BICYCLIC KETONE SULFONAMIDE COMPOUNDS | TRPV1, TRPA1, KCNJ11 | DRD2 3378/4885DRD3 3006/4885BCHE 2356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.